Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00248560 · FLOW

Participant flow

Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer · Source last updated 2019-03-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
    id
    FG000
    title
    Gemcitabine, Docetaxel
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        36
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        36
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
    id
    FG000
    title
    Gemcitabine, Docetaxel
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        36
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        36
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice